☰

Ziyang Yu, Ph.D. - Publications

Affiliations: 
2011 Boston University, Boston, MA, United States 
Area:
Biochemistry, Genetics, Oncology
Tree Info Similar researchers PubMed Report error

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Hamilton E, LoRusso P, Ma C, Vidula N, Bagley RG, Troy S, Annett M, Yu Z, Weitzman A, Conlan MG, Weise A. Abstract P5-11-01 : Phase 1 dose escalation study of a novel selective androgen receptor modulator (SARM), RAD140, in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-11-01  0.39
2020 He S, Conlan MG, Arlt H, Morris C, Yu Z. Abstract P5-05-01: Novel mechanisms of action of selective androgen receptor modulator RAD140 in AR+/ER+ breast cancer models Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-05-01  0.495
2019 Yu Z, He S, Miller C, Saeh J, Hattersley G, O'Neill A. Abstract P4-13-02: Selective androgen receptor modulator RAD140 inhibits the growth of endocrine-resistant breast cancer models with defined genetic backgrounds Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P4-13-02  0.565
2019 Hamilton E, Vidula N, Ma C, LoRusso P, Saeh J, Reichert V, Yu Z, Annett M, Weitzman A, Hattersly G, O'Neill A, Weise A. Abstract OT1-02-02: A phase 1, first-in-human, multi-part study of RAD140, an oral nonsteroidal selective androgen receptor modulator, in postmenopausal women with hormone receptor positive breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ot1-02-02  0.527
2019 Hamilton E, Vidula N, Ma C, LoRusso P, Bagley RG, Yu Z, Annett M, Weitzman A, Conlan MG, Weise A. Phase I dose escalation study of a selective androgen receptor modulator RAD140 in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer (BC) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz242.038  0.305
2017 Yu Z, He S, Wang D, Patel HK, Miller CP, Brown J, Hattersley G, Saeh JC. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor Positive Breast Cancer Models with a Distinct Mechanism of Action. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28974548 DOI: 10.1158/1078-0432.Ccr-17-0670  0.533
2017 Yu Z, He S, Wang D, Brown J, Saeh J, Hattersley G. Abstract 3609: RAD140, a selective androgen receptor modulator, has a differentiated mechanism of action in AR/ER positive breast cancers Cancer Research. 77: 3609-3609. DOI: 10.1158/1538-7445.Am2017-3609  0.57
2017 Yu Z, He S, Brown J, Miller C, Saeh J, Hattersley G. Abstract 3608: RAD140, an orally available selective androgen receptor modulator, inhibits the growth of AR/ER positive breast cancer cell line- and patient-derived xenograft models Cancer Research. 77: 3608-3608. DOI: 10.1158/1538-7445.Am2017-3608  0.575
2016 Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel E, Nelson PS, Taplin ME, Balk SP, et al. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26936914 DOI: 10.1158/1078-0432.Ccr-15-2309  0.399
2016 Yu Z, Brown J, Saeh J, Hattersley G. RAD140, an orally available selective androgen receptor modulator, exhibits potent anti-tumor activity in ER+AR+ breast cancer models European Journal of Cancer. 69: S149. DOI: 10.1016/S0959-8049(16)33042-8  0.512
2014 Cai C, He HH, Gao S, Chen S, Yu Z, Gao Y, Chen S, Chen MW, Zhang J, Ahmed M, Wang Y, Metzger E, Schüle R, Liu XS, Brown M, et al. Lysine-specific demethylase 1 has dual functions as a major regulator of androgen receptor transcriptional activity. Cell Reports. 9: 1618-27. PMID 25482560 DOI: 10.1016/J.Celrep.2014.11.008  0.346
2014 Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 4075-85. PMID 24874833 DOI: 10.1158/1078-0432.Ccr-14-0292  0.343
2014 Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1590-600. PMID 24449822 DOI: 10.1158/1078-0432.Ccr-13-1863  0.363
2014 Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis Oncogene. 33: 2815-2825. PMID 23752196 DOI: 10.1038/Onc.2013.235  0.351
2012 Romagnoli M, Belguise K, Yu Z, Wang X, Landesman-Bollag E, Seldin DC, Chalbos D, Barillé-Nion S, Jézéquel P, Seldin ML, Sonenshein GE. Epithelial-to-mesenchymal transition induced by TGF-β1 is mediated by Blimp-1-dependent repression of BMP-5. Cancer Research. 72: 6268-78. PMID 23054396 DOI: 10.1158/0008-5472.Can-12-2270  0.7
2012 Yu Z, Sato S, Trackman PC, Kirsch KH, Sonenshein GE. Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide. Plos One. 7: e33287. PMID 22438909 DOI: 10.1371/Journal.Pone.0033287  0.66
2009 Min C, Yu Z, Kirsch KH, Zhao Y, Vora SR, Trackman PC, Spicer DB, Rosenberg L, Palmer JR, Sonenshein GE. A loss-of-function polymorphism in the propeptide domain of the LOX gene and breast cancer. Cancer Research. 69: 6685-93. PMID 19654310 DOI: 10.1158/0008-5472.Can-08-4818  0.733
2009 Wang X, Belguise K, O'Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, Chalbos D, Sonenshein GE. RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Molecular and Cellular Biology. 29: 3832-44. PMID 19433448 DOI: 10.1128/Mcb.00032-09  0.608
2007 Wu M, Min C, Wang X, Yu Z, Kirsch KH, Trackman PC, Sonenshein GE. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Research. 67: 6278-85. PMID 17616686 DOI: 10.1158/0008-5472.Can-07-0776  0.708
Show low-probability matches.